Russia has a long tradition in the research and development of alternative methods for combating bacterial infections. During the Soviet era, when classic antibiotics were often scarce, there was an increased focus on bacteriophages – viruses that specifically target bacteria. This form of therapy continues to be developed and clinically applied in Russia today, as well as in countries like Georgia and Ukraine. It is considered a promising option in the fight against multidrug-resistant germs, as phages can specifically destroy bacteria against which conventional antibiotics are powerless[3].
New active ingredients from Russian research
In recent years, Russian science has also made significant progress in the field of classic antibiotic research. A current example is the discovery of the natural substance emericellipsin A by researchers at Tomsk State University. This active ingredient, derived from the alkaliphilic fungus Emericellopsis alkalina, shows exceptional efficacy against a variety of pathogens – including multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria, as well as pathogenic fungi[5].
Emericellipsin A acts on two levels: in eukaryotes such as fungi and tumor cells, it destroys the cell membrane, while in bacteria, it prevents the formation of biofilms. Biofilms are considered one of the main reasons for the resistance of many bacteria to antibiotics. By suppressing biofilm formation, emericellipsin A makes these germs susceptible again. Researchers see great potential both for single use and as a component of combination preparations. The therapy could be administered both systemically and locally[5].
The study was conducted in close cooperation with leading Russian research institutes, including the Gause Institute of New Antibiotics, the Central Research Institute of Epidemiology, and the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences. This networking underscores Russia's high scientific competence and its ability to discover and further develop innovative active ingredients[5].
Production and international networking
Despite scientific successes, Russia faces challenges in the industrial production of active ingredients. According to current reports, there are no production facilities in Russia for some of the most important antibiotic active ingredients. The country is therefore dependent on imports, which complicates supply security in the face of increasing antibiotic resistance[2].
At the same time, it is evident that Russia possesses powerful basic research capabilities and is internationally networked. Collaboration with institutes from other countries – for example, in the field of natural product research and the development of new anti-infectives – opens up opportunities to transfer research results into industrial applications and bring new therapies to market[5].
Perspectives and Challenges
Russia's potential in antibiotic research lies primarily in the following areas:
- Discovery of Novel Active Ingredients: The identification of molecules like Emericellipsin A shows that Russian laboratories are capable of finding innovative substances with a broad spectrum of activity and new mechanisms of action[5].
- Alternative Therapies: Decades of experience with bacteriophages give Russia a head start in developing non-antibiotic treatment approaches against resistant pathogens[3].
- Strong Research Networks: Cooperation between universities, state research institutes, and international partners promotes knowledge exchange and the further development of new therapies[5].
- Broad Application Prospects: New active ingredients could be used not only against infectious diseases but also in oncology and for fungal infections[5].
On the other hand, there are structural weaknesses in industrial production that need to be overcome to translate research successes into a stable supply of modern antibiotics for the population[2].
Conclusion
Russia possesses considerable scientific potential in the field of antibiotic research. The discovery of novel active ingredients and decades of experience with alternative forms of therapy such as bacteriophages make the country an important player in the global fight against multidrug-resistant pathogens. However, to fully exploit this potential, further investments in industrial production and stronger international networking are required. Only in this way can Russia contribute to overcoming the global antibiotic crisis and providing new therapies for the medicine of tomorrow[3][5][2].
Sources:
[1] Million funding for international cooperation project in … https://www.helmholtz-hips.de/de/news-events/news/detail/news/millions-in-funding-for-international-cooperation-project-in-the-field-of-anti-infectives/
[2] Only one antibiotic manufacturer left in Germany – diepta.de https://www.diepta.de/news/wirkstoffproduktion-nur-noch-ein-antibiotika-hersteller-in-deutschland
[3] Bacteriophages vs. antibiotics: Using viruses against resistance – DW https://www.dw.com/de/bakteriophagen-statt-antibiotika-mit-viren-gegen-resistenzen/a-66294473
[4] Antibiotics 2.0: A weapon against multidrug-resistant germs – Merck Group https://www.merckgroup.com/de/research/science-space/envisioning-tomorrow/precision-medicine/multidrug-resistance.html
[5] New natural antibiotic discovered in Russia – Azvision https://de.azvision.az/news/86765/neues-natur-antibiotikum-in-russland-entdeckt.html
[6] Future prospects and growth drivers for the antibiotic market https://www.forinsightsconsultancy.com/de/Berichte/Antibiotika-Markt/
[7] 3—Antibiotic resistance – a global, multifaceted … https://www.2030report.de/de/bericht/1400/kapitel/3-antibiotika-resistenzen-eine-globale-vielschichtige-herausforderung
[8] [PDF] Synthesis, biological evaluation and molecular docking studies … https://ediss.sub.uni-hamburg.de/bitstream/ediss/10170/1/Dissertation%20A.%20Dreger%2017.03.23%20cut.pdf
[9] [PDF] The race against the germs – VCI https://www.vci.de/fonds/downloads-fonds/unterrichtsmaterialien/2017-09-unterrichtsmaterial-antibiotika-textheft.pdf
[10] Sinaida Yermolyeva – Wikipedia https://de.wikipedia.org/wiki/Sinaida_Jermoljewa
[11] Pharma distribution in Russia: an underestimated giant – CHEManager https://www.chemanager-online.com/news/pharmadistribution-russland-unterschaetzter-riese
[12] Temperature-controlled drug delivery | HELMHOLTZ HIPS https://www.helmholtz-hips.de/de/news-events/news/detail/news/temperature-controlled-drug-delivery/
[13] Only one antibiotic manufacturer in Germany https://www.pharmazeutische-zeitung.de/nur-ein-antibiotika-hersteller-in-deutschland-144148/
[14] [PDF] Antibiotic resistance – BUKO Pharma Campaign https://bukopharma.de/wp-content/uploads/2017/11/2015_02_spezial_-Antibiotika.pdf
[15] Ukraine invasion, day 1064: How antibiotic resistance complicates the work … https://www.tagesspiegel.de/internationales/ukraine-invasion-tag-1064-wie-antibiotika-resistenzen-die-arbeit-der-arzte-im-ukraine-krieg-erschweren-13068616.html
[16] Medicines for Russia: Berlin pharmaceutical companies should be open … https://www.tagesspiegel.de/berlin/berliner-wirtschaft/berliner-firmen-sollten-transparenter-sein-bei-ihren-russlandgeschaften-9440138.html
[17] Pharmaceutical companies stop developing antibiotics | tagesschau.de https://www.tagesschau.de/investigativ/ndr/antibiotika-pharmakonzerne-101.html
[18] [PDF] Hurdles and prospects of new antimicrobial concepts in … – BfArM https://www.bfarm.de/SharedDocs/Downloads/DE/BfArM/Publikationen/Bundesgesundheitsblatt/2018-05-Kloss-Gerbach.pdf?__blob=publicationFile
[19] Russia's drug serialization regulations – OPTEL https://www.optelgroup.com/de/blog/was-sie-ueber-die-russischen-serialisierungsvorschriften-fuer-die-pharmabranche-wissen-muessen/
[20] New antibiotics against multidrug-resistant germs in development – VFA https://www.vfa.de/de/arzneimittel-forschung/antibiotika/neue-antibiotika
